legend biotech

Legend Biotech has emerged as one of the most closely watched companies in the cell therapy space. Headquartered in Somerset, New Jersey, with deep roots in China, this biotech firm shot to prominence thanks to its groundbreaking CAR T cell therapy for multiple myeloma. In a field dominated by giants like Bristol Myers Squibb and Novartis, Legend has proven that a focused, science driven approach can yield blockbuster results.

A Promising Player in CAR T Cell Therapy

Chimeric antigen receptor (CAR) T cell therapy reprograms a patient’s own immune cells to attack cancer. Legend Biotech’s flagship product, cilta-cel (brand name Carvykti), targets the BCMA protein found on malignant plasma cells. Developed in partnership with Janssen (the pharmaceutical arm of Johnson & Johnson), Carvykti was first approved by the FDA in 2022 for adults with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy.

What sets Legend apart is not just the therapy itself but the company’s robust manufacturing capabilities and clinical trial design. The pivotal CARTITUDE 1 study showed deep and durable responses, with many patients achieving minimal residual disease negativity. Because of these results, Carvykti quickly became a standard of care and a serious competitor to Bristol Myers’ Breyanzi and ide-cel (Abecma).

The Rise of Carvykti and Recent Milestones

In early 2024, Legend and Janssen announced a major FDA label expansion for Carvykti. The agency approved its use as an earlier line treatment for patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. This expansion opens the door to a much larger patient population and significantly boosts the therapy’s commercial potential.

Additionally, the company has made strides in manufacturing efficiency. Legend invested heavily in its own cell therapy production facility in Raritan, New Jersey, and forged partnerships to increase capacity. In the first half of 2024, Carvykti sales exceeded $400 million, and analysts project the therapy could reach multi billion dollar peak sales. This is a testament to Legend’s ability to scale a complex personalized treatment.

The stock market has responded positively: Legend Biotech’s shares (ticker LEGN) have climbed steadily, reflecting investor confidence in the growing multiple myeloma market and the company’s competitive edge.

Navigating Competition and Global Expansion

The CAR T landscape is crowded, but Legend has differentiated itself through two key strategies. First, clinical superiority: Head-to-head trials like CARTITUDE 4 have shown that Carvykti outperforms standard salvage chemotherapy regimens. Second, regulatory reach: Beyond the United States, Legend has secured approvals in Europe and China. In late 2023, the company received marketing authorization in China for relapsed or refractory multiple myeloma, tapping into one of the world’s largest patient populations.

Competitors are not sitting still. Two of the top threats include Johnson & Johnson’s own pipeline therapies and other BCMA targeted modalities like bispecific antibodies (e.g., teclistamab). However, Legend’s partnership with Janssen gives it substantial financial and development resources that few standalone biotechs can match.

• Key differentiators for Legend Biotech:
  • Deep expertise in CAR T manufacturing and supply chain.
  • Strong clinical data across multiple lines of therapy.
  • Strategic global partnerships with major pharma.
  • Active pipeline of next generation cell therapies (e.g., dual targeting, allogeneic approaches).

What Lies Ahead for Legend Biotech

Looking forward, Legend Biotech plans to expand Carvykti into earlier lines of therapy, including newly diagnosed multiple myeloma. It is also exploring combinations with other agents to improve response durability. Meanwhile, the company is advancing a pipeline of novel candidates: a next generation CAR T for solid tumors and an allogeneic “off the shelf” product that could eliminate the long manufacturing wait times.

Regulatory decisions and reimbursement policies will be crucial. In Europe, cost containment measures could slow adoption, but Legend’s value proposition (long remissions, fewer hospitalizations) supports a strong pricing argument.

For scientists and investors alike, Legend Biotech serves as a case study in how a nimble, discovery focused company can compete with the pharmaceutical giants. The story is far from over, but the foundation is rock solid.

Written by Zubair Khalid, DVM, MS, PhD. Source: original news feed and industry reports.